The Massachusetts General Hospital Endocrine Unit is a leader in investigating, diagnosing and treating disorders of bone and mineral metabolism, thyroid diseases and general endocrine conditions.
- Phone: 617-726-3966
About UsThe Massachusetts General Hospital Endocrine Unit is unique in providing patients with integrated testing and treatment across three broad areas:
- Bone and mineral metabolism disorders, such as osteoporosis and primary hyperparathyroidism
- Thyroid diseases, with a focus on hyperthyroidism (overactive thyroid), thyroid nodules and goiters, thyroid cancer and disorders of thyroid function during pregnancy
- General endocrine conditions
Our unit consists of four subspecialty units that work collaboratively to provide optimal diagnostic and therapeutic care. All four units include clinical education and training within their missions.
- The Bone Density Center offers state-of-the-art testing for the diagnosis and follow-up of osteoporosis and other metabolic bone diseases
- Endocrine Associates provides comprehensive diagnostic and therapeutic services for patients with endocrine disorders, osteoporosis and related metabolic bone diseases
- Thyroid Associates takes an efficient, comprehensive approach to diagnosing and treating thyroid disorders
- Multiple research laboratories conduct leading-edge research that improves clinical care for endocrine-related conditions
Our clinical team works closely with endocrine, thyroid and parathyroid surgeons at Mass General to coordinate patient care. In addition, many of our endocrinologists have held prominent roles in leading academic organizations, including the American Society for Bone and Mineral Research, the American Thyroid Association, the International Bone & Mineral Society, and the Endocrine Society.
A Legacy of ResearchIn the 1930s, Fuller Albright, MD, a leader in the field of endocrinology, established what is now the Endocrine Unit at Mass General. John Potts established the modern form of the Unit in 1968. More recently, our clinicians played a major role in understanding parathyroid disease and developing parathyroid hormone as a therapy for osteoporosis, which gained Food and Drug Administration approval in 2002.
Radioactive iodine treatment for hyperthyroidism was first used at Mass General, and our unit continues to break new ground through research into parathyroid hormone, Vitamin D, a recently discovered hormone called FGF23, thyroid cancer and other areas. Our endocrinologists frequently run clinical trials of promising new drugs. As a result, patients may benefit from access to the latest therapies—and to doctors with experience administering these therapies.
Educating the Next Generation Endocrine Unit faculty collaborates with faculty in the Mass General Endocrine Division to staff the Endocrine Fellowship Program. This program prepares physicians for careers in academic medicine and endocrinology. Our fellows receive clinical training at the Bone Density Center, Endocrine Associates and Thyroid Associates.
Fellows can also learn about bone and mineral metabolism from investigators in our research laboratories. For more information, please contact one of our labs.